
Mind Medicine (MNMD) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
0
Operating Income
-40.9M
Net Income
-42.7M
Balance Sheet Metrics
Total Assets
275.3M
Total Liabilities
52.5M
Shareholders Equity
222.8M
Debt to Equity
0.24
Cash Flow Metrics
Operating Cash Flow
-19.7M
Free Cash Flow
-29.4M
Revenue & Profitability Trend
Mind Medicine Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 | 0 |
Cost of Goods Sold | - | - | - | - | - |
Gross Profit | - | - | - | - | - |
Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Operating Expenses | |||||
Research & Development | 65.3M | 52.1M | 36.2M | 34.8M | 18.6M |
Selling, General & Administrative | 38.6M | 41.7M | 30.2M | 59.1M | 14.4M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 103.9M | 93.9M | 66.3M | 93.9M | 33.0M |
Operating Income | -103.9M | -93.9M | -66.3M | -93.9M | -33.0M |
Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Non-Operating Items | |||||
Interest Income | 11.6M | - | - | - | - |
Interest Expense | 2.3M | - | - | 359.0K | 164.0K |
Other Non-Operating Income | -14.0M | -6.5M | 8.0M | 20.0K | -743.0K |
Pre-tax Income | -108.7M | -95.7M | -56.8M | -94.2M | -33.9M |
Income Tax | - | - | 0 | -1.2M | 0 |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -108.7M | -95.7M | -56.8M | -93.0M | -33.9M |
Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Key Metrics | |||||
EBITDA | -91.8M | -84.2M | -71.2M | -91.2M | -33.0M |
EPS (Basic) | $-1.54 | $-2.44 | $-1.84 | $-3.45 | $-1.95 |
EPS (Diluted) | $-1.54 | $-2.44 | $-1.84 | $-3.45 | $-1.95 |
Basic Shares Outstanding | 70461067 | 39157420 | 30857463 | 27377082 | 17748039 |
Diluted Shares Outstanding | 70461067 | 39157420 | 30857463 | 27377082 | 17748039 |
Income Statement Trend
Mind Medicine Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 273.7M | 99.7M | 142.1M | 133.5M | 80.1M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | - | - | - | - | - |
Inventory | - | - | - | - | - |
Other Current Assets | 7.9M | 4.2M | 3.9M | 3.7M | 1.4M |
Total Current Assets | 281.6M | 103.9M | 146.1M | 137.2M | 81.5M |
Non-Current Assets | |||||
Property, Plant & Equipment | - | - | - | - | - |
Goodwill | 39.8M | 40.4M | 43.5M | 46.7M | 0 |
Intangible Assets | - | 527.0K | 3.7M | 6.9M | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 613.0K | 224.0K | 331.0K | - | - |
Total Non-Current Assets | 20.5M | 20.7M | 23.9M | 26.8M | 0 |
Total Assets | 302.2M | 124.5M | 170.0M | 164.0M | 81.5M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 2.0M | 4.1M | 2.1M | 4.2M | 2.0M |
Short-term Debt | - | - | 72.0K | - | - |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 24.0M | 16.5M | 9.9M | - | - |
Total Current Liabilities | 38.8M | 32.2M | 17.9M | 10.4M | 3.0M |
Non-Current Liabilities | |||||
Long-term Debt | 21.9M | 14.1M | - | - | - |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | - | 32.0K | 1.2M | 1.9M | - |
Total Non-Current Liabilities | 21.9M | 14.2M | 1.2M | 1.9M | 2.6M |
Total Liabilities | 60.7M | 46.4M | 19.1M | 12.3M | 5.7M |
Equity | |||||
Common Stock | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -398.9M | -290.2M | -194.5M | -137.7M | -44.6M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 241.4M | 78.1M | 150.9M | 151.7M | 75.9M |
Key Metrics | |||||
Total Debt | 21.9M | 14.1M | 72.0K | 0 | 0 |
Working Capital | 242.8M | 71.6M | 128.2M | 126.8M | 78.5M |
Balance Sheet Composition
Mind Medicine Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -108.7M | -95.7M | -56.8M | -93.0M | -33.9M |
Depreciation & Amortization | 527.0K | 3.2M | 3.2M | 2.6M | 0 |
Stock-Based Compensation | 16.9M | 15.5M | 13.7M | 42.7M | 7.4M |
Working Capital Changes | -2.1M | 924.0K | -3.3M | 125.0K | 544.0K |
Operating Cash Flow | -94.3M | -76.0M | -43.2M | -47.6M | -26.0M |
Investing Activities | |||||
Capital Expenditures | - | - | - | - | - |
Acquisitions | - | - | 0 | -297.0K | 0 |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | - | - | 0 | -297.0K | 0 |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 11.0M | 15.0M | 0 | - | - |
Debt Repayment | -128.0K | -844.0K | 0 | - | - |
Financing Cash Flow | 252.5M | 21.7M | 40.4M | 81.9M | 71.6M |
Free Cash Flow | -79.1M | -64.4M | -50.1M | -45.8M | -23.6M |
Net Change in Cash | 158.1M | -54.3M | -2.8M | 34.0M | 45.6M |
Cash Flow Trend
Mind Medicine Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-5.99
Forward P/E
-6.61
Price to Book
3.70
PEG Ratio
-6.61
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-59.11%
Return on Assets
-30.55%
Financial Health
Current Ratio
4.98
Debt to Equity
22.22
Beta
2.97
Per Share Data
EPS (TTM)
$-1.34
Book Value per Share
$2.45
Revenue per Share
$0.00
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
mnmd | 701.5M | -5.99 | 3.70 | -59.11% | 0.00% | 22.22 |
Vertex | 101.6B | 28.19 | 5.91 | 22.77% | 31.86% | 8.89 |
Regeneron | 60.8B | 14.45 | 1.99 | 15.34% | 31.37% | 9.04 |
Adaptive | 2.0B | -11.91 | 10.88 | -57.60% | -59.07% | 121.39 |
Arcutis | 1.9B | -14.67 | 13.97 | -57.33% | -35.40% | 79.27 |
Travere Therapeutics | 1.9B | -5.30 | 59.95 | -705.73% | -50.64% | 1,220.18 |
Financial data is updated regularly. All figures are in the company's reporting currency.